Polyrizon Ltd.
PLRZHealthcare|Biotechnology|IL
$11.04
-0.55 (-4.70%)
DCF Value
$0.81
Tangible Book / Share
$12.17
Cash / Share
$8.31
About
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Stock Price
+100.9%(1Y)
1M
+24.5%
3M
-4.7%
6M
-32.4%
YTD
+30.1%
1Y
+110.8%
3Y
-99.5%
5Y
-99.5%
Pipeline Summary
1 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
NCT07588672Seasonal Allergic Rhinitis (SAR)
N/ARecruiting
Enrollment: 120 participants
Key Facts
Market Cap$12.4M
Employees0
CEOTomer Izraeli
IPO DateOct 29, 2024
Beta-1.34
52-Week Range$2.88 – $18.2
Avg Volume52,700
ExchangeNASDAQ
Websitepolyrizon-biotech.com
Ownership
Float93.9%
Shares Outstanding1.1M
Recent Insider Trades
Izraeli TomerSELL
Mar 31, 2026500 shares @ $11.85
Carmel LironSELL
Mar 31, 2026942 shares @ $12.36
Adler OzSELL
Mar 31, 20263,292 shares @ $12.05
Carmel LironSELL
Mar 30, 2026100 shares @ $11.00
Izraeli TomerSELL
Mar 30, 20263,900 shares @ $10.90
Peers
Recent News
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Oct 27, 2026 · globenewswire.com
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
Oct 5, 2026 · globenewswire.com
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
Sep 22, 2026 · globenewswire.com
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Sep 4, 2026 · globenewswire.com
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
Sep 3, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:28 AM